FDA approves fam-trastuzumab deruxtecan-nxki for unresectable or metastatic HER2-positive breast cancer

The FDA granted accelerated approval to fam-trastuzumab deruxtecan-nxki (ENHERTU ®, Daiichi Sankyo) for patients with unresectable or metastatic HER2-positive breast cancer.

Source: FDA Center for Drug Evaluation and Research - What's New - December 20, 2019 Category: Drugs & Pharmacology Authors: FDA Source Type: news